Agile Therapeutics, Inc. (NASDAQ:AGRX) Q4 2023 Earnings Call Transcript
Agile Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.46 EPS, expectations were $-0.92.
Stay updated with breaking news from Full Year. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Agile Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.46 EPS, expectations were $-0.92.
Discover how InterCure thrives in 2023 with $95.4M revenue, despite challenges, and plans for global expansion into the U.S. and Germany.
Operator: Good morning. My name is Christa, and I will be your conference operator today.
Operator: Greetings, and welcome to the Q4 and Full Year 2023 Cepton Business Update and Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded.
Full Year Highlights 2023 revenue of $166.6 million, down 7.7% year-over-year Net loss of $11.0 million includes restructuring charges of $6.7 million and transaction fees of $3.0 millionHigh...